PCVX - NASDAQ

Vaxcyte, Inc.

PCVX·NASDAQ

$47.70

+1.1%

HealthcareBiotechnology

Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company also develops VAX-XP to protect against emerging strains and address antibiotic resistance; VAX-A1, a conjugate vaccine candidate designed to treat Group A Strep; and VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$6.89B

EPS-5.6300

P/E Ratio-8.47

Earnings Date08/05/2026

3.05B

Assets

-13%

3Y+203.0%

5Y+675.0%

10Y+7586.0%

360.45M

Total Liabilities

75%

3Y+586.0%

5Y+667.0%

10Y+4046.0%

2.69B

Total Equity

-19%

3Y+182.0%

5Y+677.0%

10Y+8580.0%

Vaxcyte, Inc. Funding & Solvency Profile

PCVX · NASDAQ

Current Assets

Cash & Cash Equivalents173.96M

Net Receivables46.56M

Inventory0.00

Other Current Assets2.80M

Total Current Assets2 B

Non-Current Assets

Property, Plant & Equipment491.72M

Goodwill & Intangible Assets0.00

Long-Term Investments883.13M

Other Non-Current Assets508.00K

Total Non-Current Assets1 B

Total Assets

3.05B

Financial Health Analysis

Current Ratio

7.91x

Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.

Debt-to-Equity Ratio

0.13x

Conservative capital structure. The company relies primarily on equity financing, indicating low financial risk.

Working Capital

1 B

Strong working capital position provides significant operational flexibility and financial cushion.

Asset Composition

53% Current

Balanced asset mix between current and non-current assets, typical of many stable businesses.

Financial Health Insight

Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.

Vaxcyte, Inc. Balance Sheet

PCVX • NASDAQ

Vaxcyte, Inc. Balance Sheet	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019	Dec 2018	Dec 2017
ASSETS
CURRENT ASSETS
Cash and Cash Equivalents	174M	387.9M	397.5M	834.7M	69M	386.2M	59M	66.1M	36.1M
Short-Term Investments	1.4B	1.4B	682.8M	96.7M	177M	0.0	0.0	0.0	0.0
Cash & Short-Term Investments	1.6B	1.7B	1.1B	931.4M	246M	386.2M	59M	66.1M	36.1M
Net Receivables	46.6M	20.7M	3.6M	0.0	0.0	0.0	0.0	0.0	0.0
Other Receivables	46.6M	20.7M	3.6M	0.0	0.0	0.0	0.0	0.0	0.0
Prepaids	17M	0.0	6.2M	11.2M	10.4M	2.8M	2.7M	578K	209K
Other Current Assets	2.8M	20.1M	6M	0.0	0.0	0.0	0.0	0.0	0.0
Total Current Assets	1.6B	1.8B	1.1B	942.6M	256.3M	389M	61.7M	66.7M	36.3M
NON-CURRENT ASSETS
Property, Plant, and Equipment (Net)	491.7M	270.1M	110.6M	31.6M	35.9M	3.3M	3.4M	3.4M	3M
Long-Term Investments	883.1M	1.4B	162.7M	26.5M	27.1M	0.0	0.0	0.0	0.0
Tax Assets	43.2M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other Non-Current Assets	508K	65.7M	38.7M	5.4M	5M	550K	584K	723K	311K
Total Non-Current Assets	1.4B	1.7B	312M	63.6M	68M	3.8M	4M	4.1M	3.3M
Total Assets	3B	3.5B	1.4B	1B	324.3M	392.8M	65.7M	70.8M	39.6M
LIABILITIES
CURRENT LIABILITIES
Total Payables	70.9M	48.5M	14.6M	9.8M	6.8M	29.8M	3.4M	2.8M	1.8M
Accounts Payable	70.9M	48.5M	14.6M	9.8M	6.8M	29.8M	3.4M	2.8M	1.8M
Accrued Expenses	23M	65.3M	112.6M	23.6M	13.2M	16.8M	7.1M	1.2M	1.3M
Short Term Debt	6.1M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Capital Lease Obligations (Current)	0.0	5.9M	7.1M	5.9M	5.3M	0.0	161K	297K	283K
Deferred Revenue	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-297K	0.0
Other Current Liabilities	105.7M	20.6M	11.1M	1.2M	3.5M	298K	433K	2.4M	850K
Total Current Liabilities	205.8M	140.2M	145.3M	40.5M	28.7M	46.9M	11.1M	6.7M	4.3M
NON-CURRENT LIABILITIES
Long Term Debt	111.4M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.8M
Deferred Tax Liabilities (Non-Current)	43.2M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other Non-Current Liabilities	-111.3M	100K	0.0	9K	96K	122K	161M	121.7M	212K
Total Non-Current Liabilities	154.7M	65.3M	22.1M	12M	11.6M	122K	161M	121.8M	4.4M
Capital Lease Obligations	111.4M	71.1M	29.2M	17.9M	16.8M	0.0	161K	458K	741K
Total Liabilities	360.5M	205.5M	167.4M	52.6M	40.3M	47M	172.1M	128.5M	8.7M
SHAREHOLDERS' EQUITY
Preferred Stock	0.0	0.0	0.0	0.0	0.0	0.0	0.0	117.8M	60.1M
Common Stock	134K	128K	98K	82K	56K	54K	7K	6K	6K
Additional Paid-In Capital	4.8B	4.7B	2.2B	1.5B	582.8M	544.4M	3M	1.3M	452K
Retained Earnings	-2.2B	-1.4B	-924.4M	-522.1M	-298.6M	-198.6M	-109.3M	-59.1M	-29.6M
Accumulated Other Comprehensive Income/Loss	1.6M	-3.9M	179K	-361K	-241K	0.0	0.0	-1.8M	0.0
Other Total Stockholders' Equity	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.8M	0.0
Total Stockholders' Equity	2.7B	3.3B	1.2B	953.6M	284M	345.8M	-106.4M	-57.7M	30.9M
Total Equity	2.7B	3.3B	1.2B	953.6M	284M	345.8M	-106.4M	-57.7M	30.9M
SUMMARY
Total Liabilities & Equity	3B	3.5B	1.4B	1B	324.3M	392.8M	65.7M	70.8M	39.6M
Total Investments	2.3B	2.7B	845.5M	123.3M	204.1M	0.0	0.0	0.0	0.0
Total Debt	228.8M	71.1M	29.2M	17.9M	16.8M	0.0	161K	458K	4.5M
Net Debt	54.9M	-316.8M	-368.2M	-816.7M	-52.2M	-386.2M	-58.8M	-65.6M	-31.6M
Shares Outstanding	130,904,923	130,904,923	130,904,923	130,904,923	130,904,923	130,904,923	130,904,923	130,904,923	130,904,923

SEC Filings

PCVX - Filing history and reports

Filing Type	Filing Date	Period Ending	Fiscal Year	Actions
10-Q 10-Q 2026 Q1 Q1	May 06, 2026	March 31, 2026	2026	View Filing
8-K 8-K 2026 N/A	May 06, 2026	May 06, 2026	2026	View Filing
DEF 14A DEF 14A 2026 N/A	April 23, 2026	June 15, 2026	2026	View Filing
8-K 8-K 2026 N/A	February 24, 2026	February 24, 2026	2026	View Filing
8-K 8-K 2026 N/A	February 24, 2026	February 24, 2026	2026	View Filing
10-K 10-K 2025 FY FY	February 24, 2026	December 31, 2025	2025	View Filing
8-K 8-K 2026 N/A	February 02, 2026	January 29, 2026	2026	View Filing
8-K 8-K 2025 N/A	December 19, 2025	December 18, 2025	2025	View Filing
8-K 8-K 2025 N/A	November 04, 2025	November 04, 2025	2025	View Filing
10-Q 10-Q 2025 Q3 Q3	November 04, 2025	September 30, 2025	2025	View Filing

Showing 1 to 10 of 93 filings

Related Guides

Blog Categories

Continue your PCVX research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.